PRIME PEOPLE | BARBARA GREEN |
BARBARA GREEN NEOSTRATA
Rosalind Hill talks to Barbara Green, VP of Clinical Affairs and Technology
at NeoStrata, about current research at the company, as well as thoughts on the future of skincare
T 56 ❚
HE PARTNERSHIP BETWEEN NeoStrata Company Inc. and Avon ® in the development of the ANEW brand ® began 20 years ago, and Barbara Green has worked for
NeoStrata for 17 of these years. Currently Vice President of Clinical
Affairs and Technology, Barbara is a pharmacist by background, and formed NeoStrata's clinical study group, working on anti-ageing technologies with the founder doctors, who were the original discoverers and pioneers of alpha hydroxy acid. And now NeoStrata is set
unleash the growth of functional collagen. As a result, collagen production is increased, with the result of a reduction in wrinkle appearance and formation.
A-F33 is an amino
acid derivative that intercepts the
mechanism which blocks the
production of
to launch a new molecule (with Avon) to the topical anti-ageing market; A-F33 (Aminofill-33), an amino acid derivative that intercepts the mechanism which blocks the production of collagen fibres, which in turn helps to
July/August 2012 |
prime-journal.com collagen fibres.
Research and development Through her work at NeoStrata ® working with the head of Research and Development ® Barbara has played a key role in developing the product for c ommer cialisa ti o n, overseeing all clinical studies surrounding any new product innovations. This role feeds into the expertise that NeoStrata has in identifying the best topical treatments for the marketplace. 'The ingredient [A-F33] was
tested to show whether it could affect characterisation of the skin, and make it softer and smoother,' says Barbara. 'Next, research was carried out which
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84